Reported about 8 hours ago
Regeneron Pharmaceuticals has successfully acquired the genetics business of 23andMe for $256 million, pulling the company out of bankruptcy. This strategic move aims to enhance Regeneron's drug discovery capabilities by utilizing DNA data. The acquisition focuses solely on 23andMe's genetics business, not its telehealth or pharmacy operations, and emphasizes a commitment to data privacy following recent concerns.
Source: YAHOO